Generic Uroxatral

Introduction

Uroxatral is a medication used to treat lower urinary‑tract symptoms caused by an enlarged prostate (benign prostatic hyperplasia, BPH). It contains the active compound alfuzosin, a selective α‑1 adrenergic antagonist, and belongs to the Men’s Health group of drugs. In the United Kingdom, alfuzosin is prescribed when bladder‑outlet obstruction is caused by BPH and when patients require a therapy that improves urinary flow without a high risk of cardiovascular adverse events.

What is Uroxatral?

Uroxatral is a film‑coated tablet formulation of alfuzosin hydrochloride. The product is manufactured by a pharmaceutical company that holds a licence to market the drug in the European Union, and it is distributed throughout the UK for adult male patients with BPH.

How Uroxatral Works

Alfuzosin binds competitively to the α‑1‑adrenoceptor subtypes that are present in the smooth muscle of the prostate, bladder neck, and urethra. By blocking these receptors, the drug reduces basal tone, leading to relaxation of the muscle and a consequent reduction in urethral resistance during voiding. The therapeutic effect appears within 2–4 hours after ingestion, with a steady‑state plasma concentration achieved after 3–5 days of once‑daily dosing. Alfuzosin is metabolised primarily by the liver (CYP3A4) and eliminated via the faeces, giving a terminal half‑life of about 5 hours in healthy adults.

Conditions Treated with Uroxatral

• Benign Prostatic Hyperplasia (BPH) with obstructive lower‑urinary‑tract symptoms (LUTS). BPH affects around 1 million men in the UK aged ≥50 years; alfuzosin improves urine flow, reduces urgency and frequency, and can delay the need for surgical intervention.

No other therapeutic indications for alfuzosin are authorised in the UK, and the drug is not approved for off‑label uses such as hypertension or cardioprotection.

Who is Uroxatral For?

• Men ≥50 years with clinically significant LUTS caused by prostate enlargement, confirmed by a urinary symptom score (e.g., International Prostate Symptom Score ≥8) and an objective assessment of bladder‑outlet obstruction.
• Patients who have failed or are unsuitable for 5‑α‑reductase inhibitors (finasteride, dutasteride) or who prefer a non‑hormonal approach.
• Individuals without severe orthostatic hypotension or significant cardiac disease (e.g., uncontrolled heart failure, recent myocardial infarction), as alfuzosin may exacerbate low‑blood‑pressure events.

Uroxatral is not appropriate for men with a known hypersensitivity to alfuzosin or any excipients, for those taking potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) without dose adjustment, or for patients with a history of severe hepatic impairment (Child‑Pugh C).

Risks, Side Effects, and Interactions

Common adverse events

• Dizziness or light‑headedness – usually transient during the first week of therapy.
• Flushing – a warm sensation, most often on the upper torso.
• Headache – mild to moderate intensity, responsive to simple analgesia.

Rare adverse events

• Hypotension (systolic <90 mmHg) – may require temporary dose reduction.
• Syncope – isolated episodes, often associated with standing after a prolonged period.
• Skin rash or pruritus – may indicate a hypersensitivity reaction.

Serious adverse events

• Severe hypotensive shock – rare, but requires immediate medical attention.
• Cardiovascular events (acute coronary syndrome, stroke) – incidence is low but higher in patients with uncontrolled cardiovascular disease.
• Fainting with injury – secondary consequences of a sudden loss of consciousness.

Clinically relevant drug–drug interactions

• CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) increase alfuzosin plasma levels; dose reduction to 10 mg on alternate days may be required.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine) lower exposure, potentially reducing efficacy.
• Nitrates (e.g., glyceryl trinitrate) – concurrent use can provoke marked hypotension; contraindicated.
• Other α‑blockers (e.g., tamsulosin) – additive effect on blood pressure; avoid combination unless clinically justified.

Practical Use: Dosing, Missed Dose, Overdose

• Standard adult dosing: 10 mg alfuzosin tablet taken orally after the same meal each day (usually a light evening meal).
• Missed dose: If a dose is omitted, take it as soon as remembered unless the next scheduled dose is within 12 hours; in that case, skip the missed dose and continue with the regular schedule.
• Overdose: Ingesting more than 30 mg in a 24‑hour period can lead to profound hypotension and syncope. If an overdose is suspected, seek urgent medical assistance; symptomatic treatment (intravenous fluids, vasopressors) is used under clinical supervision.
• Food and alcohol: Taking alfuzosin with food improves absorption and reduces gastrointestinal irritation. Alcohol may potentiate hypotensive effects; patients should limit intake while initiating therapy.
• Comorbidities: Patients with moderate hepatic impairment (Child‑Pugh A–B) may require close monitoring; severe impairment is a contraindication.

Buying Uroxatrol from Our Online Pharmacy

Uroxatral can be obtained legally through our online pharmacy in the UK. Our service provides:

• Affordable pricing, typically close to the manufacturer’s listed cost, making the generic alfuzosin option cheaper than many brand‑name products.
• Verified quality, with tablets sourced from licensed European manufacturers that comply with EU and UK pharmaceutical standards (EU‑GDP, MHRA registration).
• Guaranteed delivery, using discreet packaging and a choice of express (within 7 working days) or standard airmail (approximately 3 weeks).
• Pharmacy‑broker model, partnering with overseas licensed suppliers to give patients access to medicines that may otherwise be unavailable locally, while maintaining a high level of privacy and confidentiality.

Our online platform is designed for patients who have limited access to conventional pharmacies or who are seeking a cost‑effective generic alternative for chronic BPH management.

FAQ

• **Is alfuzosin (Uroxatral) available in both brand‑name and generic forms in the UK?
  Yes, alfuzosin is marketed under several brand names (e.g., Uroxatral, Alfuzosin®) and also as generic tablets. Generic versions contain the same active ingredient and are approved by the MHRA for the same indication, offering a lower-cost option for patients.

• **What does the Uroxatral tablet look like?
  The film‑coated tablet is typically white to off‑white, round, and bears the imprint “10 mg ALF”. Inactive ingredients include lactose, maize starch, and magnesium stearate.

• **Can Uroxatral be stored in a refrigerator?
  No, alfuzosin tablets are stable at room temperature (15‑30 °C). Refrigeration is unnecessary and may affect tablet integrity, especially the film coating.

• **Is it safe to travel overseas while taking Uroxatral?
  Yes, provided the medication is kept in its original packaging, stored at ambient temperature, and the traveller carries a copy of the prescription or a pharmacy‑issued statement to explain the medication at customs.

• **How does Uroxatral differ from older α‑blockers such as tamsulosin?
  While both agents relax prostate smooth muscle, alfuzosin has a higher affinity for α‑1‑D subtypes and a lower incidence of cardiovascular side effects. Clinical trials (e.g., VIVA‑BPH) have shown comparable efficacy with a more favourable hemodynamic profile for alfuzosin.

• **What are the specific warnings for patients with hepatic disease?
  Alfuzosin is primarily metabolised by the liver; severe hepatic dysfunction (Child‑Pugh C) is a contraindication, and moderate disease requires careful monitoring of blood pressure and potential dose adjustment.

• **Can Uroxatral be detected in routine drug‑testing panels?
  Alfuzosin is not a substance of abuse and is not included in standard workplace or forensic drug‑testing panels. It will not produce a positive result in such screens.

• **Does the formulation of Uroxatral vary between the EU and the United States?
  The European film‑coated tablet contains the same 10 mg dose of alfuzosin but may use different excipients (e.g., polymer coating types). The US formulation is often an immediate‑release tablet with distinct binder composition; however, the active ingredient and clinical effect remain equivalent.

• **Are there any special considerations for personal import of Uroxatral into the UK?
  Personal import of medicines not licensed in the UK is permitted for a maximum 3‑month supply, provided a certified copy of a prescription is available and the medication complies with EU quality standards. Importers must declare the product to HMRC and ensure it is not a controlled substance.

Glossary

α‑1‑adrenoceptor

A protein channel on smooth‑muscle cells that, when stimulated by norepinephrine, causes contraction. Blocking this receptor reduces muscle tone.

Benign Prostatic Hyperplasia (BPH)

A non‑cancerous enlargement of the prostate gland that commonly affects older men and can obstruct urinary flow.

CYP3A4

An enzyme in the liver that metabolises many drugs, including alfuzosin; inhibition or induction of this enzyme alters alfuzosin concentrations.

Therapeutic window

The range of drug concentrations in which the medication is effective without causing unacceptable toxicity.

⚠️ Disclaimer

The information provided about Uroxatral is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Uroxatral for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.